Fig. 7: Pharmacokinetic properties, biodistribution, and safety profiles of SAProsomes.
From: Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity
a Drug concentration in the plasma of Sprague-Dawley rats (n = 3 rats/group) following a single administration of different drugs at a 17.5 mg/kg of MSA-2 equivalent dose. Data are presented as ± s.d. of the mean. b Pharmacokinetic parameters reflecting half-life (t1/2), C0, Cmax, area under the curve (AUC0–t) and mean residence time (MRT). Mice bearing MC38 (c), 4T1 (d), or B16F10 (e) xenograft tumors were given a single dose of MSA-2 and SAProsome-3 (n = 6 mice/group). Drug concentration in tumors and lymph nodes was determined using HPLC analysis at 8 and 24 h after administration. Data are presented as the mean ± s.d. and statistically analyzed using one-way analysis of variance. f, g C57BL/6 mice were treated with free MSA-2 orally at a dose of 240 mg/kg or intravenously at a dose of 60 mg/kg, and SAProsome-3 intravenously at a dose of 45 mg/kg per mouse, every three days for a total of three injections (n = 4 mice/group). Blood chemistry of mice were analyzed on day 8 postadministration. Box plot conveys median (middle line), 25th and 75th percentiles (box), and the minima to maxima range (whiskers). Data are statistically analyzed using one-way analysis of variance. h The levels of interleukin 6 (IL-6) in the serum and other tissues were determined using ELISA at 6 h postadministration of free MSA-2 (PO, 240 mg/kg), free MSA-2 (IV, 60 mg/kg) or SAProsome-3 (IV, 45 mg/kg) (n = 5). Source data are provided as a Source data file.
